Vistagen gets FDA feedback on fasedienol Phase 3 path, reports Q2 FY2027 resultsNov 13Quarterly updateVistaGen Therapeutics, Inc.
VistaGen gets FDA feedback on Phase 3 path for fasedienol in social anxiety disorderNov 9Regulatory milestoneVistaGen Therapeutics, Inc.
VistaGen cuts workforce by about 31%, citing focus on Phase 3 fasedienol workOct 30RestructuringVistaGen Therapeutics, Inc.
VistaGen expands severance plan terms for executives beyond change-in-control eventsOct 9PeopleVistaGen Therapeutics, Inc.
Vistagen reports preliminary open-label data from PALISADE-4 extension for fasedienolSep 22Clinical readoutVistaGen Therapeutics, Inc.
Vistagen plans FDA meeting on fasedienol path after mixed PALISADE-4 dataAug 14Quarterly updateVistaGen Therapeutics, Inc.
Vistagen reports Phase 2 repeat dose results for fasedienol in social anxiety disorderAug 6Clinical readoutVistaGen Therapeutics, Inc.
Vistagen's fasedienol misses primary endpoint in PALISADE-4 trialJun 30Clinical readoutVistaGen Therapeutics, Inc.